SCHEMBL5622255

SCHEMBL5622255

COc1ccc(C(O)c2sc3cnccc3c2Nc2ccc3c(c2)CC/C3=N\O)cc1

nearest known ligand 0.61

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
BRAF P15056 20/20 0.61
EIF2AK3 Q9NZJ5 1/20 0.35
MAPK3 P27361 1/20 0.34
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14566748 1.00 BRAF (0.61) BRAFEIF2AK3MAPK3MAPK1
SCHEMBL4765087 1.00 BRAF (0.61) BRAFEIF2AK3MAPK3MAPK1
SCHEMBL5622260 1.00 BRAF (0.61) BRAFEIF2AK3MAPK3MAPK1
SCHEMBL4722321 0.84 BRAF (0.78) BRAFMAPK3MAPK1
SCHEMBL4722320 0.84 BRAF (0.78) BRAFMAPK3MAPK1
SCHEMBL4762938 0.82 BRAF (0.71) BRAFEIF2AK3
SCHEMBL4764465 0.82 BRAF (0.66) BRAFEIF2AK3
SCHEMBL4761978 0.82 BRAF (0.66) BRAFEIF2AK3
SCHEMBL4762950 0.82 BRAF (0.71) BRAFEIF2AK3
SCHEMBL4761966 0.82 BRAF (0.66) BRAFEIF2AK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070049603-A1 Raf inhibitor compounds and methods of use thereof ARRAY BIOPHARMA INC. 2007-03-01 US claimed
US-20070049603-A1 Raf inhibitor compounds and methods of use thereof ARRAY BIOPHARMA INC. 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049603-A1 Raf inhibitor compounds and methods of use thereof BRAF, RAF1, ARAF BRAF 1/4885EIF2AK3 2123/4885MAPK3 48/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.